Electromed Inc (ELMD) — Titan Protect Analysis

ELMD

Electromed Inc

Healthcare · ·

$37.69

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$305M

Total market value of the company

Trailing P/E

31.48

Premium valuation

Forward P/E

60.38

Based on estimated future earnings — lower means cheaper

Rev Growth

+18.4%

Year-over-year revenue change

Profit Margin

14.1%

How much profit the company keeps from each dollar of revenue

ROE

21.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$40.00

+6% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About Electromed Inc

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral scl

https://smartvest.com

Country: United States Employees: 177 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.162

Excellent risk-adjusted returns

Kelly Fraction

0.0906

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.213

Returns exceed worst-case losses — strong risk profile

Annual Return

59.3%

Historical annualised return based on price data

Max Drawdown

-48.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.39

Very low correlation to market moves

52W High

$40.00

6% below the year high

52W Low

$17.73

113% above the year low

Avg Volume

53,977

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$1.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.17

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

78.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

20.3%

Profit from core operations before interest and tax

Free Cash Flow

$8M

Positive — the business generates more cash than it spends

Revenue (TTM)

$72M

Total revenue over the last 12 months

Net Income

$10M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$45.00

Target Median

$40.00

Target Low

$36.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go